In recent years there has been a widely acknowledged, if unconfirmed, assumption that men initially diagnosed with low-risk prostate cancer (clinical stage T1-2a, PSA < 10 ng/ml; and Gleason 3 + 3 = 6 or lower) had plenty of time to come to a good decision about their management options, and did not need to […]![]()
